ADC Technology Market

ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    July 2023

  • Pages
    407

  • View Count
    153686

Example Insights

The image provides context of ADC technology market. With the rising demand for more efficient and homogenous antibody drug conjugates, drug developers are increasingly collaborating with technology providers, for leveraging their advanced ADC linker and ADC conjugation technologies This image highlights ADC technology companies. At present, over 95 ADC linker and conjugation technologies are being offered by various technology developers across the globe; around 55% of these are third-generation technologies We have distributed the antibody conjugation market landscape, which is highly fragmented, featuring the presence of both new entrants and well-established players across key geographies The infographic highlights level of innovation happening in ADC technology domain. Over 2,100 patents have been filed / granted for ADC linker and ADC conjugation technologies, by industry and non-industry players, to protect the intellectual property generated within this field
We have looked at positioning of various ADC technology companies. To cater to the increasing demand for homogenous ADC therapies, a number of players have stepped up to introduce technologically advanced platforms and establish a strong brand position in this industry The image looks at the partnerships in ADC technology domain. Since 2021, a considerable increase in partnership activity has been witnessed in this domain; ~70% of the deals were related to licensing of technologies, primarily focused on product development and R&D purposes We have also tried to identify the likely partners for ADC technology companies. ADC drug developers are anticipated to continue to form strategic alliances with ADC linker and conjugation technology providers to further strengthen their respective technology portfolios The infographic analyses business model being adopted by ADC tecnology providers. Stakeholders have adopted different business models to maximize the gain from ADC technologies; a considerable number of players have signed multiple partnerships to out-license their technologies
We have also looked at the competitiveness of companies and technologies in ADC domain. In pursuit of gaining a competitive edge, stakeholders are actively enhancing their existing capabilities to improve their respective technology portfolios and compliance to evolving industry standards The images provides case study on ADC therapeutics. At present, over 350 ADC therapeutic candidates are undergoing clinical trials for the treatment of various oncological disorders; majority of these ADCs are being evaluated as monotherapies We have presented a detailed analysis on adc technology market sizing. With the growing focus on development of efficacious and site-selective drugs, the ADCs linker and conjugation technologies market is anticipated to witness an annualized growth of ~15%, over the next decade The ADC technology market forecast is well-segmented. The estimated market opportunity is projected to be well distributed across different types of linkers and key geographical regions

Report Description

ADC Technology Overview: ADC Linker and Antibody Conjugation

The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during the forecast period. Antibody drug conjugates have emerged as a promising alternative to the conventional anti-cancer therapies. Till date, around 14 ADCs have received the USFDA approval, while over 420 antibody drug conjugates are currently being evaluated under different stages of development. Antibody drug conjugate is a complex and versatile class of biotherapeutics, in which linker moiety is attached to the cytotoxic payload. However, the complex structure and design of antibody drug conjugates poses a greater challenge in overall tolerability and efficacy of the molecule. As a result, more advanced and efficacious antibody drug conjugate technology is required to generate the controlled assembly of antibody drug conjugates while maintaining tolerability and safety profiles. Antibody / ADC conjugation technologies generally involve modification / engineering of an antibody in order to conjugate it with a payload /  linker-drug moiety. On the other hand, ADC linker technologies involve development of a structural moiety to link the payload with an antibody in a reliable manner with desired payload delivery mechanics. These technologies are optimized to produce homogenous antibody drug conjugate with high drug to antibody ratio (DAR). In fact, ADCs developed using these technologies have demonstrated improved stability and efficacy in tumor micro-environment.

Homogenous ADCs with optimized linker technologies offer reduced immunogenicity, enabling the targeted delivery of linker-payload complex at the desired site without having any side effects. Owing to the aforementioned advantages, several start-ups and established players have entered the field of ADC linker and conjugation technologies, offering novel conjugation / bioconjugation technologies, more potent payloads and advanced linker chemistries. These players have inked several licensing agreements to advance their ADC development programs. It is worth mentioning that researchers and antibody drug conjugate developers are actively relying on ADC linker and conjugation technology companies that offer technical expertise and experience in this market. Driven by the growing demand for antibody drug conjugates, the ADC linker and conjugation technologies market is anticipated to witness substantial market growth during the forecast period.

Key Market Insights

The Antibody Drug Conjugates: Focus on ADC Linker and Conjugation Technologies (2nd Edition) - Distribution by Generation of Technology (Third-Generation, Second-Generation and Next-Generation), Type of Conjugation (Chemical, Chemoenzymatic and Chemical), Type of Linker (Cleavable and Non-Cleavable), Type of Payment Model Adopted (Upfront Payments and Milestone Payments), and Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities associated with the ADC linker and antibody conjugation industry, during the given forecast period. The market report highlights efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the ADC technology market are briefly discussed below.

Rising Interest in ADC Linker and Antibody Conjugation Technology for the Development of Homogenous Antibody Drug Conjugate

In 2000, the USFDA approved the first ADC, Mylotarg. However, it was withdrawn voluntarily from the market due to safety concerns and poor clinical benefits of the product. With continued research in the area of ADCs, innovators have identified various factors that determine the success of an antibody drug conjugate; these include structure and design of an antibody drug conjugate, systemic toxicity, validation of tumor biomarkers, choice of antibody and potency of the payload. The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies. These technologies have the potential to develop antibody drug conjugates with improved stability and toxicity profile, while maintaining efficient release of the cytotoxic payload at the desired location. The most important characteristic of these technologies is the production of controlled, homogenous ADCs, which are site-selective and can be utilized as a targeted anti-cancer therapy. We anticipate that the growing demand for targeted, stable and non-toxic ADCs will continue to drive the adoption and market growth of ADC linker technology and antibody conjugation technologies for development of antibody drug conjugates during the forecast period.

Current Market Landscape of ADC Technologies

The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies. These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC. It has been observed that the majority of the antibody drug conjugates generated via these ADC technologies are site specific, have high tolerability and precise DAR ratio. In addition, we believe that third-generation technologies are poised to play a significant role in shaping the future market landscape, by enabling the development of new therapeutic modalities that were previously considered unattainable. The constant evolution of ADC linkers and conjugation technologies will support the development of novel and more efficacious ADCs. In turn, the growing ADC therapy market will drive the demand for these technologies, contributing to substantial CAGR of ADC technology market during the forecast period.

ADC Technology Market Size

The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at a CAGR of ~15% during the forecast period. Driven by the growing interest of stakeholders in addressing the efficiency and safety related concerns with antibody drug conjugates, the ADC linker and conjugation technologies market is anticipated to witness tremendous market growth in the foreseen future. 

Based on mechanism of drug release, the linkers are categorized as cleavable or non cleavable linkers. Majority of the approved ADCs use cleavable linkers and based on the current late-stage pipeline of ADCs, the global ADC technology market is anticipated to be driven by cleavable linkers in the short term.

North America and Europe to Compete for the Largest Share of ADC Linker and Antibody Conjugation Technologies Market

Close to 80% of the market share is estimated to be captured by companies based in North America and Europe. This can be attributed to the escalating partnership activity in these regions. It is interesting to note that 78% of the total deals were inked by players based in North America and Europe during the time period, 2014-2023. Further, some of the companies based in these developed regions, such as Mersana Therapeutics, Seattle Genetics and Zymeworks offer several antibody conjugation and ADC linker technology / platforms. These platforms are either second-generation or third-generation technologies that offer chemical site specific conjugation. Moreover, all these players have in-house ADC portfolio for testing the potential of their technologies and resulting in the development of innovative cancer therapies.

Adoption of Different Business Models by the ADC Linker and Antibody Conjugation Technology Companies

The growing demand for antibody drug conjugates for the treatment of various forms of cancer, especially breast cancer, has paved the way for continued innovation in antibody conjugation technologies. In order to access these advanced ADC technologies for the development of antibody drug conjugate, several business deals have been inked over the past few years. It is interesting to note that technology out-licensing and collaborative research are the most popular type of business models adopted by stakeholders in this industry. It is worth highlighting that Synaffix has received / is likely to receive close to USD 5.5 billion from out licensing their ADC conjugation platform. In June 2023, Lonza acquired Synaffix, getting access to the latter’s ADC technologies for payload and site-specific linkers. Another company, Mersana Therapeutics expects to receive nearly USD 2 billion in total payments from their collaborative research efforts with several stakeholders engaged in ADC development. Substantial investments like these, along with ongoing technological innovations, will act as the key driver behind the evolution of ADC linker and antibody conjugation technologies market during the forecast period.

Partnership Activity in ADC linker and ADC Conjugation Technologies Market

In recent years, several partnerships have been inked by various stakeholders in order to consolidate their presence and enhance their capabilities and product portfolio to meet the growing demand for antibody drug conjugates. In fact, the partnership activity has witnessed a CAGR of ~30% in the past three years. Licensing agreements, product development agreements, and research and development agreements are the most common types of partnerships that have been inked in this industry.

In March 2022, Seattle Genetics entered into a research and development agreement with Sanofi for the development of three targets, focused on targeting cancer. In addition, it was observed that Mersana Therapeutics has signed several deals over the past few years for the development of various ADC candidates, targeting a wide array of cancers, including breast cancer, gastric cancer and non-small cell lung cancer. The growing interest in novel antibody drug conjugates and rising number of deals focused on advancing conventional therapies for targeting various oncological indications will continue to drive the ADC technology market over the coming years.

Leading Companies in the ADC Conjugation Technologies Market

Examples of key players engaged in ADC technology industry (which have also been profiled in this report) include (in alphabetical order), Alteogen, Ambrx, Antikor, Catalent Biologics, Heidelberg Pharma, Iksuda Therapeutics, LegoChem Biosciences, Mersana Therapeutics, NBE-Therapeutics, Seattle Genetics and Sutro Biopharma. This market report includes an easily searchable, excel database of all the companies providing ADC technology related to ADC linkers or ADC conjugation worldwide.

Recent Developments in ADC Technology Market

Several recent developments have taken place in the field of ADC technology. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In July 2023, Ambrx announced that the FDA has granted Fast Track designation to ARX517, an proprietary investigational anti-PSMA antibody-drug conjugate therapy, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor. 
  • In July 2023, Mersana Therapeutics announced the publication of UPLIFT clinical trial’s topline data for the patients suffering from platinum-resistant ovarian cancer and strategic reprioritization. 
  • In June 2023, Ambrx announced the closing of registered market price by raising USD 75 million.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in ADC technology market, across different segments, as defined in the table below:

Key Report Attributes Details
Forecast Period 2023 – 2035

Historical Period

2017-2022

CAGR

~15%

Generation of Technology

  • Third-Generation
  • Second-Generation
  • Next-Generation

Type of Conjugation

  • Chemical
  • Chemoenzymatic
  • Enzymatic

Type of Linker

  • Cleavable
  • Non-cleavable

Type of Payment Model Adopted

  • Upfront Payments
  • Milestone Payments
Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Key Companies Profiled

  • Alteogen
  • Ambrx
  • Antikor
  • Catalent Biologics
  •  Heidelberg Pharma
  • Iksuda Therapeutics
  • LegoChem Biosciences
  • Mersana Therapeutics
  •  NBE-Therapeutics
  • Seattle Genetics
  • Sutro Biopharma

(Full list of 65+ companies captured in the market landscape analysis of the report)

Customization Scope

15% Free Customization Option
Powerpoint Presentation (Complimentary)

Available

Excel Data Packs

  • Market Landscape Analysis
  • Technology Competitiveness Analysis
  • Patent Analysis
  • Partnership and Collaborations
  • Business Model Analysis
  • Likely Partner Analysis
  • Brand Positioning Analysis
  • Case Study: ADC Therapeutics Market Landscape
  • Market Forecast and Opportunity Analysis

The market report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry. Amongst other elements, the market research report includes:

  • An executive summary of the key insights captured during our research, offering a high-level view on the current state of the ADC linker and antibody conjugation technologies market and its likely evolution in the short to mid and long term.
  • A brief introduction to the concept of antibody drug conjugates, its various components, mechanisms of action and advantages over traditional targeted therapies. The chapter emphasizes on the role of ADC linker and antibody conjugation technologies in the development of ADC therapeutics. Subsequently, it provides an overview of different types of linkers and conjugation technologies, listing their specifications. It also features a brief discussion on the challenges related to the development of associated technologies, offering insights on anticipated future trends.
  • A detailed review of the overall landscape of ADC linker and conjugation technologies, based on a number of parameters, such as type of technology (antibody conjugation technology, linker technology, linker-payload technology, and antibody linker and conjugation technology), availability of licensing, generation of ADC technology (first-generation, second-generation, third-generation and next-generation), site specificity (site specific, non-specific , and both, site specific / non-specific), type of conjugation (chemical, chemoenzymatic and enzymatic),  drug antibody ratio, compatible linker (cleavable, non-cleavable, and both, cleavable / non-cleavable), conjugation chemistry (cysteine-based, click chemistry, lysine-based, transpeptidation using enzymes, maleimide-based, glycan conjugation and others), conjugation site (engineered, modified, endogenous and exogenous), type of linker (cleavable, non-cleavable,  and both, cleavable / non-cleavable). It also includes information on ADC linker and antibody conjugation technology companies, based on several parameters, such as their year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe, and Asia-Pacific and rest of the world).
  • An in-depth technology competitiveness analysis of ADC linker and conjugation technologies, segmented into three categories, namely small (2-50 employees), mid-sized (51-500 employees) and large (>500 employees) players. Within the respective peer groups, technologies were ranked based on various relevant parameters, such as portfolio strength (based on the years of experience), technology competitiveness (based on parameters, such as status of technology, availability of licensing, generation of technology, site specificity, type of conjugation, drug antibody ratio, compatible linker, conjugation chemistry, conjugation site and drugs developed using a technology), as well as partnership activity (in terms of number of partnerships). The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
  • Tabulated profiles of prominent companies that are currently engaged in offering ADC linker and ADC conjugation technologies. Each profile features a brief overview of company (with information on year of establishment, number of employees, location of headquarters and key members of the leadership team), details related to their respective technology portfolio, recent developments and an informed future outlook.
  • A detailed review of the patents that have been filed / granted for ADC linker and ADC conjugation technologies during the time period 2018-2023, based on important parameters such as, type of patent, publication year, application year,  number of granted patents and patent applications, patent jurisdiction, focus area, CPC symbols, patent age, type of applicant (on the basis of number of patents), and individual patent assignees (in terms of size of intellectual property portfolio). It also features a detailed patent benchmarking analysis and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations)
  • An analysis of the partnerships inked between various stakeholders for ADC technologies, during the period 2014-2023, featuring a detailed set of analysis based on various parameters, such as year of partnership, type of partnership, type of partner, generation of technology, type of linker, type of conjugation, target therapeutic area(s), most popular technologies, most active players and geographical location of the companies.
  • An insightful analysis on business models adopted by various ADC technology providers engaged in this industry along with the information on parameters, such as year of partnership, purpose of partnership (merger / acquisition, product commercialization, product development, product distribution, research, research and development, technology / product integration, technology transfer), type of business strategy adopted (technology-out licensing, technology-in licensing, product out-licensing, product in-licensing, collaborative research and others), type of investment (upfront payments and milestone payments), amount invested and most active players.
  • An in-depth analysis of over 85 antibody drug conjugate therapeutics developers that are likely to partner with ADC linker and conjugation technology companies in the near future, based on several relevant parameters, such as developer score (based on year of establishment and company size), portfolio score (based on type of linker and antibody structure), pipeline score (based on stage of development of a drug and number of pre-clinical molecules) and therapeutic area.
  • An insightful brand positioning analysis of prominent antibody conjugation technology providers (shortlisted based on the number of conjugation technologies developed), highlighting the current perceptions regarding their proprietary technologies by taking into consideration several relevant aspects, such as experience of the technology provider, number of technologies offered, product diversity, number of patents and number of partnerships.
  • A detailed case study on overall landscape of the antibody drug conjugates market, based on a number of parameters, such as stage of development, target disease indication, therapeutics area, line of treatment, dosing frequency, type of therapy, target antigen, antibody isotype, payload / cytotoxin / warhead, payload type, type of linker, type of linker (cleavable / non-cleavable). It also features details on antibody drug conjugate developers, including information on their year of establishment, company size and location of headquarters and most active players.
  • A detailed market forecast analysis to estimate the existing market size and the future opportunity for ADC linker and antibody conjugation technologies supporting ADC development, during the given forecast period, 2023-2035. The overall opportunity has been distributed across various segments, such as generation of technology (third-generation, second-generation, and next-generation), type of conjugation (chemical, chemoenzymatic and enzymatic), type of linker (cleavable and non-cleavable), type of payment model adopted (Upfront payments and milestone payments), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by our discussions with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Cedric Lizin (Board Member, Singzyme)
  • Jiaqiang Cai (Co-Founder and Chief Scientific Officer, MedLink Therapeutics)
  • Kai Uhrig (Head of Strategy and Business Development, Merck KGaA)
  • Saptarshi Ghosh (Scientist II, Abzena)
  • Mary Chaohong Hu (Chief Executive Officer, Miracogen)
  • Floris van Delft (Chief Scientific Officer, Synaffix)
  • Jan Modregger (Head of Research and Development, Eucodis Bioscience)
  • Okuzumi-Tatsuya (General Manager, Research and Development, Ajinomoto) and Brian Mendelsohn (Director of ADC Process Development and Tech Transfer, Ajinomoto)
  • Wouter Verhoeven (Former Chief Business Officer, NBE-Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is antibody conjugation technology?

Answer: Antibody conjugation technology refers to a technology that is designed to increase the absorption of cytotoxic drug molecules at the desired location, resulting in the formation of site specific homogenous antibody drug conjugates.

Question 2: What is an ADC linker?

Answer: Linker is one of the components of an ADC. It helps in connecting antibody with the cytotoxic payload.

Question 3: What types of linkers are used in antibody drug conjugates?

Answer: Two types of linkers are used in ADCs; cleavable linkers, which release the cytotoxic payload near the desired location resulting in killing of the tumor and neighboring cells and non-cleavable linkers, which release the potent payload at the desired site minimizing off-site toxicity.

Question 4: What is site specific conjugation of ADC?

Answer: Site specific conjugation of ADC refers to attaching the linker to a defined site on an antibody resulting in the production of homogeneous and controlled structures of antibody drug conjugate.

Question 5: What are the technologies used in ADC?

Answer: Antibody drug conjugate industry conventionally use three technologies; first-generation, second generation and third generation. However, now-a-days, next generation technologies are also emerging, offering development of site specific ADCs.

Question 6: What are the key factors driving the ADC linker and antibody conjugation technologies market?

Answer: The ADC linker and antibody conjugation technologies market is currently driven by the growing prevalence of oncological disorders, ageing population and increased interest of researchers in novel therapeutic interventions.

Question 7: Which types of partnerships are forged by ADC linker and ADC conjugation technology providers?

Answer: Licensing agreements, product development and R&D agreements are the most common partnership models adopted by stakeholders engaged in the ADC linker and conjugation technologies market.

Question 8: Which are the leading technology providers in the ADC conjugation market?

Answer: Leading technology providers include Alteogen, Ambrx, Antikor, Catalent Biologics, Heidelberg Pharma, Iksuda Therapeutics, LegoChem Biosciences, Mersana Therapeutics, NBE-Therapeutics, Seattle Genetics and Sutro Biopharma.

Question 9: Which region has the highest market share in ADC linker and conjugation technologies market?

Answer: North America and Europe capture around 80% share in the global ADC linker and conjugation technologies market. Emerging regions, such as Asia-Pacific, are likely to grow relatively fast in the long term.

Question 10: What is the likely growth rate (CAGR) of ADC linker and conjugation technologies market?

Answer: The global market size for ADC linker and ADC conjugation technologies is anticipated to grow at a compound annualized growth rate (CAGR) of ~15% during the forecast period 2023-2035.

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2 Antibody Drug Conjugates (ADCs)
3.2.1 Components of ADCs
3.2.1.1 Antibody
3.2.1.2 Cytotoxin
3.2.1.3 Linker

3.3. Advantages of ADCs Over Conventional Therapeutics
3.4. ADC Linker Technologies
3.4.1. Non-cleavable Linkers
3.4.2. Cleavable Linkers

3.4. ADC Conjugation Technologies
3.4.1. Chemical Conjugation
3.4.2. Enzymatic Conjugation

3.5. Future Perspectives

4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Availability of Licensing

4.3. ADC Conjugation Technologies
4.3.1. Analysis by Generation of Technology
4.3.2. Analysis by Site Specificity
4.3.3. Analysis by Type of Conjugation
4.3.4. Analysis by Drug Antibody Ratio
4.3.5. Analysis by Compatible Linker
4.3.6. Analysis by Conjugation Chemistry
4.3.7. Analysis by Conjugation Site

4.4. ADC Linker and ADC Linker-Payload Technologies
4.4.1. Analysis by Type of Linker

4.5. ADC Linker and Conjugation Technology Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Year of Establishment and Location of Headquarters
4.5.5. Analysis by Company Size and Location of Headquarters

4.6. ADC Conjugation Technologies Service Providers

5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1 Technologies Offered by Small Companies
5.4.2 Technologies Offered by Mid-sized Companies
5.4.3 Technologies Offered by Large Companies

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.1.2. Company Overview
6.2.1.3. Financial Information
6.2.1.4. Technology Portfolio
6.2.1.5. Recent Developments and Future outlook

6.2.2. Catalent Biologics
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Technology Portfolio
6.2.2.4. Recent Developments and Future outlook

6.2.3. Mersana Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Technology Portfolio
6.2.3.4. Recent Developments and Future outlook

6.2.4. Seagen
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Technology Portfolio
6.2.4.4. Recent Developments and Future outlook

6.2.5. Sutro Biopharma
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Technology Portfolio
6.2.5.4. Recent Developments and Future outlook

6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.1.1. Company Overview
6.3.1.2. Technology Portfolio
6.3.1.3. Recent Developments and Future outlook

6.3.2. Iksuda Therapeutics
6.3.2.1. Company Overview
6.3.2.2. Technology Portfolio
6.3.2.3. Recent Developments and Future outlook

6.3.3. Heidelberg Pharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Technology Portfolio
6.3.3.4. Recent Developments and Future outlook

6.3.4. LinXis Biopharmaceuticals
6.3.4.1. Company Overview
6.3.4.2. Technology Portfolio
6.3.4.3. Recent Developments and Future outlook

6.3.5. NBE-Therapeutics
6.3.5.1. Company Overview
6.3.5.2. Technology Portfolio
6.3.5.3. Recent Developments and Future outlook

6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.4.1.1. Company Overview
6.4.1.2. Technology Portfolio
6.4.1.3. Recent Developments and Future outlook

6.5.2. LegoChem Biosciences
6.5.2.1. Company Overview
6.5.2.2. Technology Portfolio
6.5.2.3. Recent Developments and Future outlook

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Application Year
7.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4. Analysis by Patent Jurisdiction
7.3.5. Analysis by CPC Symbols and Sections
7.3.6. Analysis by Type of Applicant
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.3.8. Leading Non-Industry Players: Analysis by Number of Patents
7.3.9. Leading Patent Assignees: Analysis by Number of Patents

7.4. Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics

7.5. Patent Valuation
7.6. Leading Patents by Number of Citations

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partnership and Generation of Technology
8.3.5. Analysis by Type of Partnership and Type of Linker
8.3.6. Analysis by Type of Partnership and Type of Conjugation
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year of Partnership and Type of Partner
8.3.9. Analysis by Type of Partnership and Type of Partner
8.3.10. Analysis by Target Therapeutic Area(s)
8.3.11. Most Active Players: Analysis by Number of Partnerships
8.3.12. Most Popular Technologies: Analysis by Number of Partnerships

8.4. Regional Analysis
8.4.1. Local and International Agreements
8.4.12. Intercontinental and Intracontinental Agreements

9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Business Strategies
9.4. ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.4.1. Analysis by Purpose of Partnership
9.4.2. Analysis by Year of Partnership and Purpose of Partnership
9.4.3. Analysis by Type of Business Strategy Adopted
9.4.4. Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.4.5. Analysis by Upfront and Milestone Payments
9.4.6. Analysis by Type of Business Strategy Adopted and Deal Value

9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.1.1. Analysis by Purpose of Partnership
9.5.1.2. Analysis of Technology Out-Licensing Deals by Deal Value

9.5.2. LegoChem Biosciences
9.5.2.1. Analysis by Purpose of Partnership
9.5.2.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.2.3. Analysis of Technology Out-Licensing Deals by Amount of Investment

9.5.3. Catalent Biologics
9.5.3.1. Analysis by Purpose of Partnership
9.5.3.2. Analysis by Year of Partnership and Business Strategy Adopted

9.5.4. Sutro Biopharma
9.5.4.1. Analysis by Purpose of Partnership
9.5.4.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4.3. Analysis of Technology Out-Licensing Deals by Deal Value

9.5.5. Heidelberg Pharma
9.5.5.1. Analysis by Purpose of Partnership
9.5.5.2. Analysis by Year of Partnership and Business Strategy Adopted

9.5.6. Mersana Therapeutics
9.5.6.1. Analysis by Purpose of Partnership
9.5.6.2. Analysis by Year of Partnership and Business Strategy Adopted

9.7. Concluding Remarks

10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology

10.4. Potential Strategic Partners in North America
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.4.4. Least Likely Partners

10.5. Potential Strategic Partners in Europe
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
10.5.4. Least Likely Partners

10.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1. Most Likely Partners
10.6.2. Likely Partners
10.6.3. Less Likely Partners
10.6.4. Least Likely Partners

11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis

12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.2.1. Analysis by Stage of Development
12.2.2. Analysis by Target Disease Indication(s)
12.2.3. Analysis by Therapeutic Area(s)
12.2.4. Analysis by Line of Treatment
12.2.5. Analysis by Dosing Frequency
12.2.6. Analysis by Type of Therapy
12.2.7. Analysis by Target Antigen
12.2.8. Analysis by Antibody Isotype
12.2.9. Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10. Analysis by Type of Payload
12.2.11. Analysis by Linker
12.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)

12.3. Antibody Drug Conjugate: List of Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
12.3.4. Analysis by Company size and Location of Headquarters
12.3.5. Most Active Players: Analysis by Number of Therapies

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2017-2035
13.4.1. ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
13.4.1.1. ADC Linker and Conjugation Technologies Market for Third-Generation Technologies 2023-2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies 2023-2035
13.4.1.3. ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035

13.4.2. ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
13.4.2.1. ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035
13.4.2.2. ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035
13.4.2.3. ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035

13.4.3. ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
13.4.3.1. ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035
13.4.3.2. ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035

13.4.4. ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
13.4.4.1. ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035
13.4.4.2. ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035

13.4.5. ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
13.4.5.1. ADC Linker and Conjugation Technologies Market in North America, 2023-2035
13.4.5.1.1. ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035
13.4.5.1.2. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035
13.4.5.1.3. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035

13.4.5.2. ADC Linker and Conjugation Technologies Market in Europe, 2023-2035
13.4.5.2.1. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035
13.4.5.2.3. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035

13.4.5.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035
13.4.5.3.1. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035
13.4.5.3.2. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035
13.4.5.3.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, 2023-2035

13.5. Concluding Remarks

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Saptarshi Ghosh (Scientist II)

14.3. MedLink Therapeutics
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Jiaqiang Cai (Co-Founder and Chief Scientific Officer)

14.4. Merck KGaA
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Kai Uhrig (Head of Strategy and Business Development)

14.5. Singzyme
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Cedric Lizin (Board Member)

14.6. Ajinomoto
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Okuzumi-Tatsuya (General Manager, Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer)

14.7. Eucodis Bioscience
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Jan Modregger (Head of Research and Development)

14.8. NBE-Therapeutics
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Wouter Verhoeven (Former Chief Business Officer)

14.9. Shanghai Miracogen
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Mary Chaohong Hu (Chief Executive Officer)

14.10. Synaffix
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Floris van Delft (Chief Scientific Officer)

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 2.2 Executive Summary: Patent Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Business Model Analysis
Figure 2.5 Executive Summary: Case Study on ADC Therapeutics
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Components of ADCs
Figure 3.2. Types of Linkers
Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by Availability of  Licensing
Figure 4.3. ADC Conjugation Technologies: Distribution by Generation of Technology
Figure 4.4. ADC Conjugation Technologies: Distribution by Site Specificity
Figure 4.5. ADC Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.6. ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Figure 4.7. ADC  Conjugation Technologies: Distribution by Compatible Linker
Figure 4.8. ADC  Conjugation Technologies: Distribution by Conjugation Chemistry
Figure 4.9. ADC  Conjugation Technologies: Distribution by Conjugation Site 
Figure 4.10. ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Figure 4.11. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Figure 4.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Figure 4.13. ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Figure 4.14. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 4.15. ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters 
Figure 5.1 Technology Competitiveness Analysis: Distribution of Technologies Offered by Small Companies
Figure 5.2 Technology Competitiveness Analysis: Distribution of Technologies Offered by Mid-sized Companies
Figure 5.3 Technology Competitiveness Analysis: Distribution of Technologies Offered by Large Companies
Figure 6.1 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Figure 6.2 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Figure 6.3. Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Figure 6.4 Seagen: Revenues, 2018-2022 (USD Billion)
Figure 6.5 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Figure 6.6 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year
Figure 7.3. Patent Analysis: Cumulative Distribution by Application Year
Figure 7.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Figure 7.5. Patent Analysis: Distribution by Patent Jurisdiction
Figure 7.6. Patent Analysis: Distribution by CPC Symbols and Sections
Figure 7.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 7.9. Leading Industry Players: Distribution by Number of Patents
Figure 7.10. Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.11. Leading Patent Assignees: Distribution by Number of Patents
Figure 7.12. Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 7.13. Patent Analysis: Distribution by Patent Age
Figure 7.14. ADC Linker and Conjugation Technologies: Patent Valuation
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Figure 8.7. Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.9. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.10. Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Figure 8.11. Most Active Players: Distribution by Number of Partnerships
Figure 8.12. Most Popular Technologies: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Local and International Agreements
Figure 8.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Business Models Analysis: Distribution by Purpose of Partnership
Figure 9.2 Business Models Analysis: Year-wise Distribution by Purpose of Partnership
Figure 9.3 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Figure 9.4 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Figure 9.5 Business Models Analysis: Distribution by Upfront and Milestone Payments
Figure 9.6. Business Models Analysis: Distribution by Type of Business Strategy Adopted and Deal Value
Figure 9.7. Synaffix: Distribution by Purpose of Partnership
Figure 9.8. Synaffix: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.9. LegoChem Biosciences: Distribution by Purpose of Partnership
Figure 9.10. LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.11. LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.12. Catalent Biologics: Distribution by Purpose of Partnership
Figure 9.13. Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.14. Sutro Biopharma: Distribution by Purpose of Partnership
Figure 9.15. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.16. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.17. Heidelberg Pharma: Distribution by Purpose of Partnership
Figure 9.18. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.19. Mersana Therapeutics: Distribution by Purpose of Partnership
Figure 9.20. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 11.1 Brand Positioning Analysis: Competitive Advantage
Figure 11.2 Brand Positioning Analysis: Reasons to Believe
Figure 11.3 Brand Positioning Matrix: Abzena
Figure 11.4 Brand Positioning Matrix: Ambrx
Figure 11.5 Brand Positioning Matrix: Byondis
Figure 11.6. Brand Positioning Matrix: Creative Biolabs
Figure 11.7. Brand Positioning Matrix: Eisai
Figure 11.8. Brand Positioning Matrix: Mersana Therapeutics
Figure 11.9. Brand Positioning Matrix: Sorrento Therapeutics
Figure 11.10. Brand Positioning Matrix: Tubulis
Figure 12.1. Antibody Drug Conjugates: Distribution by Stage of Development
Figure 12.2. Antibody Drug Conjugates: Distribution by Target Disease Indication(s)
Figure 12.3. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Figure 12.4. Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 12.5. Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 12.6. Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 12.7. Antibody Drug Conjugates: Distribution by Target Antigen
Figure 12.8. Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 12.9. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Figure 12.10. Antibody Drug Conjugates: Distribution by Type of Payload
Figure 12.11. Antibody Drug Conjugates: Distribution by Linker
Figure 12.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 12.13. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 12.14. Antibody Drug Conjugates Developers: Distribution by Company Size
Figure 12.15. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Figure 12.16. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Figure 12.17. Most Active Players: Distribution by Number of Therapies
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Technology Licensing Deal: Payment Structure
Figure 13.3 Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2023-2035 (USD Million)
Figure 13.4 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Figure 13.5 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035 (USD Million)
Figure 13.6 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035 (USD Million)
Figure 13.7 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035 (USD Million)
Figure 13.8 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Figure 13.9 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035 (USD Million)
Figure 13.10 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.11 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.12 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Figure 13.13 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.14 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.15 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Figure 13.16 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035 (USD Million)
Figure 13.17 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035 (USD Million)
Figure 13.18 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.19 ADC Linker and Conjugation Technologies Market in North America, 2023-2035 (USD Million)
Figure 13.20 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.21 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.22 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.23 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035 (USD Million)
Figure 13.24 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.25 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.26 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.27 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 13.28 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.29 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.30 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 15.1 Concluding Remarks: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 15.2 Concluding Remarks: Patent Analysis
Figure 15.3 Concluding Remarks: Partnerships and Collaborations
Figure 15.4 Concluding Remarks: Business Model Analysis
Figure 15.5 Concluding Remarks: Current Market Landscape of ADC Therapeutics
Figure 15.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1. Commonly Used Cytotoxins in ADC Therapeutics
Table 3.2 OEL Bands: Guidelines by SafeBridge Consultants
Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 4.2. ADC Conjugation Technologies: Information on Generation of Technology, Site-Specificity, Type of Conjugation and Drug Antibody Ratio
Table 4.3. ADC Conjugation Technologies: Information on Number of Steps Involved, Compatible Linker, Conjugation Chemistry and Conjugation Site
Table 4.4. ADC Linker and Linker-Payload Technologies: Information on Type of Linker and Linker Name
Table 4.5. ADC Linker and Conjugation Technologies: List of Technology Providers
Table 4.6. ADC Linker and Conjugation Technologies: List of Service Providers
Table 6.1. ADC Linkers and Conjugation Technologies: List of Profiled Companies
Table 6.2. Ambrx: Company Overview
Table 6.3. Ambrx: ADC Linkers and Conjugation Technologies Portfolio
Table 6.4. Ambrx: Antibody Drug Conjugates Portfolio
Table 6.5. Ambrx: Recent Developments and Future Outlook
Table 6.6. Catalent Biologics: Company Overview
Table 6.7. Catalent Biologics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.8. Catalent Biologics: Antibody Drug Conjugates Portfolio
Table 6.9. Catalent Biologics: Recent Developments and Future Outlook
Table 6.10. Mersana Therapeutics: Company Overview
Table 6.11. Mersana Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.12. Mersana Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.13. Mersana Therapeutics: Recent Developments and Future Outlook
Table 6.14. Seagen: Company Overview
Table 6.15. Seagen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.16. Seagen: Antibody Drug Conjugates Portfolio
Table 6.17. Seagen: Recent Developments and Future Outlook
Table 6.18. Sutro Biopharma: Company Overview
Table 6.19. Sutro Biopharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.20. Sutro Biopharma: Antibody Drug Conjugates Portfolio
Table 6.21. Sutro Biopharma: Recent Developments and Future Outlook
Table 6.22. Antikor: Company Overview
Table 6.23. Antikor: ADC Conjugation Technology Portfolio
Table 6.24. Antikor: Antibody Drug Conjugates Portfolio
Table 6.25. Antikor: Recent Developments and Future Outlook
Table 6.26. Iksuda Therapeutics: Company Overview
Table 6.27. Iksuda Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.28. Iksuda Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.29. Heidelberg Pharma: Company Overview
Table 6.30. Heidelberg Pharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.31. Heidelberg Pharma: Antibody Drug Conjugates Portfolio
Table 6.32. Heidelberg Pharma: Recent Developments and Future Outlook
Table 6.33. LinXis: Company Overview
Table 6.34. LinXis: ADC Conjugation Technology Portfolio
Table 6.35. NBE-Therapeutics: Company Overview
Table 6.36. NBE-Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.37. NBE-Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.38. Alteogen: Company Overview
Table 6.39. Alteogen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.40. Alteogen: Antibody Drug Conjugates Portfolio
Table 6.41. LegoChem Biosciences: Company Overview
Table 6.42. LegoChem Biosciences: ADC Linkers and Conjugation Technologies Portfolio
Table 6.43. LegoChem Biosciences: Antibody Drug Conjugates Portfolio
Table 6.44. LegoChem Biosciences: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: Top CPC Sections
Table 7.2. Patent Analysis: Top CPC Symbols
Table 7.3. Patent Analysis: Top CPC Codes
Table 7.4. Patent Analysis: Summary of Benchmarking Analysis
Table 7.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 7.6. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 8.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
Table 8.2. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, Information on Type of Partner, Therapeutic Area(s) and Type of Agreement (Region-wise and Geography-wise)
Table 9.1. ADC Linker and Conjugation Technologies: Business Model Analysis
Table 10.1. North America: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.2. North America: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.3. North America: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.4. North America: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.5. Europe: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.6. Europe: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.7. Europe: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.8. Europe: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.9. Asia-Pacific and Rest of the World: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.10. Asia-Pacific and Rest of the World: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.11. Asia-Pacific and Rest of the World: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.12. Asia-Pacific and Rest of the World: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 12.1. Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Stage of Development, Target Disease Indication(s) and Therapeutics Area(s)
Table 12.2. Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosage Frequency, Type of Therapy, Target Antigen and Antibody Isotype
Table 12.3. Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
Table 12.4. Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 13.1. Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2. ADC Linker and Conjugation Technologies: Average Upfront Payments and Average Milestone Payments (USD Million)
Table 14.1 Abzena: Company Snapshot
Table 14.2. MedLink Therapeutics: Company Snapshot
Table 14.3 Merck KGaA: Company Snapshot
Table 14.4 Singzyme: Company Snapshot
Table 14.5 Ajinomoto: Company Snapshot
Table 14.6 Eucodis Bioscience: Company Snapshot
Table 14.7 NBE-Therapeutics: Company Snapshot
Table 14.8 Shanghai Miracogen: Company Snapshot
Table 14.9 Synaffix: Company Snapshot
Table 16.1 ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 16.2 ADC Linker and Conjugation Technologies: Distribution by Availability of Licensing
Table 16.3 ADC Conjugation Technologies: Distribution by Generation of Technology
Table 16.4 ADC Conjugation Technologies: Distribution by Site Specificity
Table 16.5 ADC Conjugation Technologies: Distribution by Type of Conjugation
Table 16.6 ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Table 16.7 ADC Conjugation Technologies: Distribution by Compatible Linker
Table 16.8 ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Table 16.9 ADC Conjugation Technologies: Distribution by Conjugation Site
Table 16.10 ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Table 16.11 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Table 16.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Table 16.13 ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Table 16.14 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Table 16.15 ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Table 16.16 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Table 16.17 Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Table 16.18 Seagen: Revenues, 2018-2022 (USD Billion)
Table 16.19 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Table 16.20 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Table 16.21 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Table 16.22 Patent Analysis: Distribution by Type of Patent
Table 16.23 Patent Analysis: Cumulative Distribution by Publication Year
Table 16.24 Patent Analysis: Cumulative Distribution by Application Year
Table 16.25 Patent Analysis: Distribution by Patent Type and Publication Year
Table 16.26 Patent Analysis: Distribution by Patent Jurisdiction
Table 16.27 Patent Analysis: Distribution by CPC Symbols and Sections
Table 16.28 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.29 Leading Industry Players: Distribution by Number of Patents
Table 16.30 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.31 Leading Individual Assignees: Distribution by Number of Patents
Table 16.32 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Table 16.33 Patent Analysis: Distribution by Patent Age
Table 16.34 ADC Linker and Conjugation Technologies: Patent Valuation
Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.38 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Table 16.39 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Table 16.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Table 16.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 16.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.44 Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Table 16.45 Most Active Players: Distribution by Number of Partnerships
Table 16.46 Most Popular Technologies: Distribution by Number of Partnerships
Table 16.47 Partnership and Collaborations: Local and International Agreements
Table 16.48 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.49 Business Models Analysis: Distribution by Purpose of Partnership
Table 16.50 Business Models Analysis: Distribution by Year of Partnership and Purpose of Partnership
Table 16.51 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Table 16.52 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Table 16.53 Business Models Analysis: Distribution by Upfront and Milestone Payments
Table 16.54 Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Table 16.55 Synaffix: Distribution by Purpose of Partnership
Table 16.56 Synaffix: Technology Out-Licensing Deals by Deal Value
Table 16.57 LegoChem Biosciences: Distribution by Purpose of Partnership
Table 16.58 LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.59 LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.60 Catalent Biologics: Distribution by Purpose of Partnership
Table 16.61 Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.62 Sutro Biopharma: Distribution by Purpose of Partnership
Table 16.63. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.64. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.65. Heidelberg Pharma: Distribution by Purpose of Partnership
Table 16.66. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.67. Mersana Therapeutics: Distribution by Purpose of Partnership
Table 16.68. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.69. Antibody Drug Conjugates: Distribution by Stage of Development
Table 16.70. Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 16.71. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Table 16.72. Antibody Drug Conjugates: Distribution by Line of Treatment
Table 16.73. Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 16.74. Antibody Drug Conjugates: Distribution by Type of Therapy
Table 16.75. Antibody Drug Conjugates: Distribution by Target Antigen
Table 16.76. Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 16.77. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Table 16.78. Antibody Drug Conjugates: Distribution by Type of Payload
Table 16.79. Antibody Drug Conjugates: Distribution by Linker
Table 16.80 Antibody Drug Conjugates: Distribution by Type of Linker
Table 16.81. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 16.82. Antibody Drug Conjugates Developers: Distribution by Company Size
Table 16.83. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Table 16.84. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Table 16.85. Most Active Players: Distribution by Number of Antibody Drug Conjugates
Table 16.86 Global ADC Linker and Conjugation Technologies Market, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.87 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Table 16.88 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Table 16.92 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.93 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Table 16.96 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Table 16.99 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 16.102 ADC Linker and Conjugation Technologies Market in North America, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.104 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.105 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

 

  1. 2BScientific
  2. 3SBio
  3. Ab Studio
  4. AbbVie
  5. Abcam
  6. AbClon
  7. ABL Bio
  8. Abnova
  9. AbTis
  10. Abzena
  11. ACES Pharma
  12. Adagene
  13. ADC Biotechnology
  14. ADC Therapeutics
  15. Adcendo
  16. Adcentrx Therapeutics
  17. Advanced Proteome Therapeutics
  18. Affinity Life Sciences
  19. AGC Biologics
  20. Agensys
  21. AIMEDBIO
  22. Ajinomoto
  23. Albumedix
  24. Allozyne
  25. Alpha Cancer Technologies
  26. Alphamab Oncology
  27. AlphaThera
  28. Alteogen
  29. AltruBio (formerly known as AbGenomics)
  30. Ambrx
  31. Amgen
  32. Angiex
  33. Antengene
  34. Antikor
  35. Apexigen
  36. Aptamer
  37. Araris Biotech
  38. Asana BioSciences
  39. Astellas Pharma
  40. AstraZeneca
  41. Atara Biotherapeutics
  42. ATB Therapeutics
  43. Atreca
  44. Avacta
  45. Avipep Therapeutics
  46. Bayer
  47. BeiGene
  48. Bicycle Therapeutics
  49. Binghamton University
  50. BioAtla
  51. Biocytogen
  52. BioLegend
  53. BioMed Valley Discoveries
  54. BiOneCure Therapeutics
  55. BioNova Pharmaceuticals
  56. BioOutsource
  57. Bio-Rad
  58. Biosion
  59. Biosynth
  60. Bio-Synthesis
  61. BioTechnique
  62. Bio-Thera Solutions
  63. BIOZOL
  64. BiVictriX Therapeutics
  65. Bliss Biopharmaceutical
  66. BOC Sciences
  67. Boehringer Ingelheim
  68. Bolt Biotherapeutics
  69. Boster Bio
  70. Boston College
  71. BrickBio
  72. Bristol-Myers Squibb
  73. BSP Pharmaceuticals
  74. Byondis
  75. Cancer Research UK
  76. Capra Science
  77. CARBOGEN AMCIS
  78. Cardinal Health
  79. Catalent Biologics
  80. CEL Healthcare Fund
  81. Celgene
  82. Cell Signalling Technology
  83. Cellectar Biosciences
  84. CellMosaic
  85. Celltrion
  86. Centrose
  87. Cerbios-Pharma
  88. Charite – Universitatsmedizin Berlin
  89. Chiome Bioscience
  90. Chong Kun Dang Pharmaceutical
  91. Constellation Pharmaceuticals
  92. Corbus Pharmaceuticals
  93. Creative Biolabs
  94. Creative Diagnostics
  95. Creative Peptides
  96. Cristal Therapeutics
  97. CSPC Pharmaceutical
  98. CStone Pharmaceuticals
  99. CT Pharma and Biotechnology Research and Development
  100. CureMeta
  101. CytomX Therapeutics
  102. Daiichi Sankyo
  103. Dakewe
  104. Dalton Pharma Services
  105. Dantari
  106. Debiopharm
  107. Diatheva
  108. DualityBio
  109. Eisai
  110. Elevation Oncology
  111. EMD Serono
  112. Emergence Therapeutics
  113. Envigo
  114. EUCODIS Bioscience
  115. Everest Biotech
  116. Exelixis
  117. Expedeon
  118. Femtogenix
  119. Fleet Bioprocessing
  120. Formosa Laboratories
  121. Formosa Pharmaceuticals
  122. Fortis Therapeutics
  123. Fosun Pharma
  124. Fudan University
  125. Funakoshi
  126. Genentech
  127. GeneQuantum Healthcare
  128. Genmab
  129. Genor Biopharma
  130. Genovis
  131. GenScript
  132. Genzyme
  133. Gilead Sciences
  134. Glycotope
  135. Glykos
  136. Goodwin Biotechnology
  137. GlaxoSmithKline
  138. Hangzhou Adcoris Biopharma
  139. Hangzhou DAC Biotech
  140. Hansoh Pharma
  141. Harbour BioMed
  142. Heidelberg Pharma
  143. Hisun Pharmaceuticals
  144. HOPU Investments
  145. Hummingbird Bioscience
  146. iBIOSOURCE
  147. Iconic Therapeutics
  148. Iksuda Therapeutics (formerly known as Glythera)
  149. ImmuneOncia Therapeutics
  150. ImmunoBiochem
  151. ImmunoGen
  152. Immunome
  153. Immunomedics
  154. Innate Pharma
  155. INNOVATE
  156. Innovent Biologics
  157. Interchim
  158. IntoCell
  159. Intravacc
  160. IONTAS
  161. iProgen Biotech
  162. Janssen Biotech
  163. Janssen Pharmaceuticals
  164. Jazz Pharmaceuticals
  165. Kairos Therapeutics
  166. KLUS Pharma
  167. Kyowa Hakko Kirin
  168. LabClinics
  169. LakePharma
  170. LaNova Medicines
  171. Lantheus
  172. Laronde
  173. LegoChem Biosciences
  174. Leinco Technologies
  175. Lepu Biopharma
  176. Levena Biopharma
  177. Light Chain Bioscience
  178. LinXis
  179. Lonza
  180. Lundbeck
  181. Luzsana Biotechnology
  182. Mablink
  183. MabPlex
  184. MabSpace Biosciences
  185. Mabwell
  186. MacroGenics
  187. Magenta Therapeutics
  188. Maine Biotechnology
  189. McSAF
  190. medac
  191. MediaPharma
  192. MediLink Therapeutics
  193. MedImmune
  194. Meditope Biosciences
  195. MedKoo Biosciences
  196. Megalith Pharmaceuticals
  197. Menarini
  198. Merck KGaA
  199. Mersana Therapeutics
  200. Millennium Pharmaceuticals
  201. Mitsubishi Tanabe Pharma
  202. Momenta Pharmaceuticals
  203. Multitude Therapeutics
  204. MuseChem
  205. Mythic Therapeutics
  206. NanoValent Pharmaceuticals
  207. National Cancer Center Research Institute Japan
  208. National Cancer Institute
  209. National Research Council Canada
  210. Navrogen
  211. NBE-Therapeutics (acquired by Boehringer Ingelheim)
  212. Nektar Therapeutics
  213. Nerviano Medical Sciences
  214. NextCure
  215. Nordic Nanovector
  216. Noria Therapeutics
  217. NovaRock Biotherapeutics
  218. Novartis
  219. Novatein Biosciences
  220. Novelty Nobility
  221. NovoCodex Biopharmaceuticals
  222. Novozymes
  223. OBI Pharma
  224. OcyonBio
  225. OGD2 Pharma
  226. Oncolinx
  227. Oncomatryx
  228. Oncotec Pharma Produktion
  229. OnCusp Therapeutics
  230. Orano Med
  231. OriGene
  232. OS Therapies
  233. Oxford BioTherapeutics
  234. Paul Scherrer Institute
  235. Peak Bio
  236. Perseus Proteomics
  237. Pfizer
  238. Pharmaron
  239. Pheon Therapeutics
  240. Pierre Fabre
  241. PinotBio
  242. Pioneering Medicines
  243. Piramal Pharma Solutions
  244. PolyTherics
  245. Principia Biopharma
  246. ProBioGen
  247. ProfoundBio
  248. Progenics Pharmaceuticals
  249. ProteoGenix
  250. Pyxis Oncology
  251. Quadira Biosciences
  252. Quartzy
  253. Rakuten Medical
  254. Recepta Biopharma
  255. Redwood Bioscience
  256. Regeneron
  257. RemeGen Biosciences
  258. Revance Therapeutics
  259. Roche
  260. Rocket Pharmaceuticals
  261. Rockland Immunochemicals
  262. Sanofi
  263. Sapphire Bioscience
  264. Sapporo Medical University
  265. SATT Conectus
  266. Schengen Pharma
  267. Scripps Research
  268. Seagen
  269. Seramun Diagnostica
  270. Shanghai Fosun Pharmaceutical
  271. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  272. Shanghai Institute of Materia Medica
  273. Shanghai Miracogen
  274. Shanghai Pharma Biotherapeutics
  275. Singzyme
  276. Sinotau Pharmaceutical
  277. Sorrento Therapeutics
  278. SOTIO
  279. SouthernBiotech
  280. Spirea
  281. Sungwoo LifeSciences
  282. Sunomix Therapeutics
  283. Sutro Biopharma
  284. Synaffix
  285. Syndivia
  286. Syngene
  287. Synthon
  288. SystImmune
  289. Takeda
  290. Takeda Oncology
  291. Tanabe Research Laboratories
  292. Targinta (a subsidiary of Xintela)
  293. Tasly Biopharmaceuticals
  294. TBD Pharmatech (formerly known as TBD-Biodiscovery)
  295. The Academy of Military Science
  296. The Johns Hopkins University School of Medicine
  297. ThioLogics
  298. Toray
  299. TOT Biopharm
  300. TRIO Pharmaceuticals
  301. Triphase Accelerator
  302. Tsuchikama Laboratory
  303. Tubulis
  304. Ubix Therapeutics
  305. UCB
  306. University College London
  307. University Medical Center Groningen
  308. Vaccinex
  309. Vall d’Hebrón Institute of Oncology
  310. Vall d’Hebron University Hospital
  311. Vaxcyte
  312. Vector Laboratories
  313. Vincerx Pharma
  314. Welsh, Carson, Anderson & Stowe
  315. WuXi PharmaTech
  316. Y-Biologics
  317. Zhejiang Teruisi Pharmaceutical
  318. ZIP Solutions
  319. Zydus
  320. Zymeworks

Source 1: https://pubs.rsc.org/en/content/articlehtml/2017/sc/c6sc05149a
Source 2: https://aacrjournals.org/clincancerres/article/17/20/6389/76679/Antibody-Conjugate-Therapeutics-Challenges-and

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com